Navigation Links
Cephalon Announces Issuance of Patent for AMRIX
Date:6/17/2008

n the United States include: TREANDA(R) (bendamustine hydrochloride) for injection, AMRIX, PROVIGIL(R) (modafinil) Tablets [C-IV], FENTORA(R) (fentanyl buccal tablet) [C-II], TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; manufacturing development and capabilities; market prospects for its products, including AMRIX; sales and earnings guidance; and other statements regarding matters that are not historical facts, including statements regarding the AMRIX patent. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
2. Cephalon Notified of Generic Fentanyl Buccal Tablet Filing
3. Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain
4. Cephalon Quarterly Conference Call Invitation
5. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
6. Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
7. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
8. Cephalon General Counsel John E. Osborn to Resign Position
9. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... , and ANN ARBOR, Mich. ... small cohort published OncoTargets and Therapy today ... better than Foundation Medicine,s FoundationOne test across a number ... clinically actionable biomarker targets. The purpose of ... commercially available NGS platforms for profiling cancer patients compared ...
(Date:4/28/2015)... DE (PRWEB) April 28, 2015 The ... organizations that work together to lower barriers to innovation ... Ontologies Mapping project. , The Ontologies Mapping project ... establish best practices for ontology management in life sciences ... a set of standardized guidelines, tools and services to ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 More than ... psychosis at some point over the course of their ... symptoms that worsen as the disease progresses. ReachMD ... announces the launch of a series dedicated to PD ... in PD, movement disorders, and psychiatric conditions. , The ...
(Date:4/28/2015)... According to a 2013 report from the American ... from burn injuries per year. Despite several advances in ... scars with subsequent contractures remains a major problem in ... no adequate treatment. Contractures are a permanent tightening of ... permanent deformity. , Synedgen has developed a new ...
Breaking Biology Technology:Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 2Paradigm Cancer Diagnostic Test (PCDx) Performed Better Than FoundationOne In Side by Side Clinical Study 3Pistoia Alliance Announces Start of Ontologies Mapping Project 2ReachMD Launches Series Focusing on Parkinson’s Disease Psychosis 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 3
... , LEXINGTON, Ky. , ... based in Lexington, KY announced today that its ... created and characterized the world,s first rat model of severe ... complete lack of the major components of the immune system. ...
... 6 Omnio Healer AB, a pioneer company,developing novel ... has entered into a partnership agreement with Eden,Biodesign. Under ... production services relating to Omnio Healer,s lead,recombinant protein candidate. ... therapeutic concept for wound healing and,anti-infection, Omnio Healer is ...
... WALTHAM, Mass., Aug. 6 Repligen Corporation (Nasdaq: ... 2010, ended June 30, 2009. Total revenue for the quarter ... quarter of fiscal year 2009. The prior year results were ... Company for royalties on the U.S. sales of Orencia(R) prior to ...
Cached Biology Technology:Transposagen Creates a Rat Model of the Human Immune System 2Transposagen Creates a Rat Model of the Human Immune System 3Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments 2Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments 3Repligen Reports First Quarter Fiscal Year 2010 Financial Results 2Repligen Reports First Quarter Fiscal Year 2010 Financial Results 3Repligen Reports First Quarter Fiscal Year 2010 Financial Results 4Repligen Reports First Quarter Fiscal Year 2010 Financial Results 5Repligen Reports First Quarter Fiscal Year 2010 Financial Results 6Repligen Reports First Quarter Fiscal Year 2010 Financial Results 7
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/6/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market, announced ... for MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM ... NXT-ID introduces a new revolutionary method and system ... use of miniature antenna modules for multiple purposes ...
(Date:4/1/2015)... Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market, announces the ... wallets is underway to early access pre-order customers. ... usage at retail outlets including Walmart, Target, AT&T, Dunkin, ... Wocket was accepted at all outlets and very easy ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... from the University of California at San Francisco (UCSF) ... dedicated to the brain that the controversy is over: ... dead. , The cerebral cortex is a sheet of ... that process particular aspects of sensation, movement and cognition. ...
... of genes has shed light on the role of gene ... in Proceedings of the National Academy of Sciences USA, was ... , Dr Robert Beiko, Professor Mark Ragan and Mr ... in an effort to map how genes are shared between ...
... used by the U.S. military to track vehicle convoys in ... little-known world of pygmy elephants in Borneo. , ... elephant's being captured and outfitted with a collar that can ... the first time, the public can track the movements of ...
Cached Biology News:MIT researcher presents new view of how the cortex forms 2Lateral thinking produces first map of gene transmission 2WWF peeks into mysterious life of Borneo's pygmy elephants 2
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
WNV Core Antibody...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from ... Human FANCM. (Note: the amino acid ... available as ab27787 .) ...
Biology Products: